NCT03255447View on ClinicalTrials.gov

Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 3, 2019

Study Completion Date

April 3, 2019

Conditions
Autoimmune Membranous Nephropathy
Interventions
DEVICE

Immunoadsorption

Fresenius Globaffin

Trial Locations (3)

M13 9WL

Central Manchester University Hospital Foundation Trust, Manchester

PR2 9HT

Royal Preston Hospital, Preston

M6 8HD

Salford Royal Infirmary, Salford

All Listed Sponsors
collaborator

Fresenius AG

INDUSTRY

lead

Manchester University NHS Foundation Trust

OTHER_GOV

NCT03255447 - Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy | Biotech Hunter | Biotech Hunter